Rat monoclonal antibody to pS62-MYC

Case ID:
Web Published:


MYC is a proto-oncogene associated with tumor pathogenesis in multiple cancer types, but currently there is a lack of reliable antibodies to assess MYC levels in FFPE patient samples. OHSU researchers have developed a rat monoclonal Serine 62 phosphorylated MYC antibody, which recognizes a form of MYC associated with increased protein stability and oncogenic activity, for use in immunohistochemistry applications in human and mouse tissues.

Technology Overview

MYC activation is associated with unchecked cellular proliferation and identification of MYC in patient histological samples could aid in tumor diagnosis, prognosis and clinical research. However, tumor biopsies are typically preserved as formalin fixed paraffin embedded (FFPE) specimens, and currently available MYC antibodies are largely unreliable in immunohistochemistry (IHC) and immunofluorescence (IF) applications. The laboratory of Dr. Rosalie Sears has developed a rat monoclonal MYC antibody for use in FFPE samples (see Figure)­. The antibody detects Serine 62 phosphorylated forms of MYC (pS62 MYC), and can be used for initial detection and quantification of pS62 MYC levels as well as localization within a specimen. This antibody shows broad utility for additional applications beyond IHC and IF, including immunoprecipitations and chromatin immunoprecipitations. The antibody shows specific nuclear labeling in mouse and human FFPE tissues, consistent with MYC’s predominate known subcellular localization. This antibody provides a new avenue to assess Serine 62 phosphorylated MYC levels in FFPE patient samples.